Compare GoPro Inc (GPRO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? GoPro Inc trades at $1.18 (market cap $253.82M), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 504.9× GoPro Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GPRO | VRTX | |
|---|---|---|
Market Cap | $253.82M | $128.16B |
Volume | 9,909,466 | 806,603 |
Sector | Technology | Health |
52-Week High | $2.35 | $557.96 |
52-Week Low | $0.58 | $407.37 |
Typical Hold Time | 45 Days | 120 Days |
Enterprise Value | $312.60M | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.18, down 10.61% today amid volatile trading following recent merger announcements. The stock shows bullish technical signals with oversold RSI conditions, while fundamentally the company faces significant challenges with negative profit margins and declining revenue. Recent developments include a proposed $285 million merger with Starman Optical and influencer Markiplier taking an 8.5% stake, driving substantial price volatility.
Investment outlook remains highly speculative with the merger offering potential upside from the $1.14 buyout price, but fundamental weakness and negative cash flow pose substantial risks. Analyst sentiment is mixed with only 21% recommending buy, while ongoing investigations into the merger's fairness add uncertainty to the transaction's completion.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
